Quality-of-life Benefits and Harms from Prostate Radiotherapy in Patients with Low-burden Metastatic Prostate Cancer

Affiliations

¹ Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: trevor_royce@med.unc.edu.
² Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
³ Department of Radiation Oncology, University of Kansas, Kansas City, KS, USA.

Editorial

Trevor J Royce et al. Eur Urol. 2021 Feb.

. 2021 Feb;79(2):198-199.

doi: 10.1016/j.eururo.2020.09.029. Epub 2020 Sep 24.

¹ Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: trevor_royce@med.unc.edu.
² Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
³ Department of Radiation Oncology, University of Kansas, Kansas City, KS, USA.

No abstract available

Comment on

Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.
Boevé L, Hulshof MCCM, Verhagen PCMS, Twisk JWR, Witjes WPJ, de Vries P, van Moorselaar RJA, van Andel G, Vis AN. Boevé L, et al. Eur Urol. 2021 Feb;79(2):188-197. doi: 10.1016/j.eururo.2020.08.023. Epub 2020 Sep 22. Eur Urol. 2021. PMID: 32978014 Clinical Trial.